BioCorRx, a developer and provider of solutions in the treatment of substance use disorders, has engaged IRISYS, LLC, a contract pharmaceutical product development and manufacturing services company, for the development and manufacturing of BICX102, a multi-month sustained release naltrexone implant. The company plans to conduct clinical trials and seek FDA approval for BICX102 as a treatment for opioid and alcohol use disorders.
 
“We look forward to partnering with such a reputable partner as IRISYS to manufacture our naltrexone implant,” said Brady Granier, chief executive officer and president, BioCorRx. “Having received the National Institute on Drug Abuse grant award last month and following a pre-IND meeting we had with the FDA last year, we are now in a position to begin the manufacturing and development process for our lead pharmaceutical candidate, BICX102. IRISYS brings valuable experience beyond manufacturing that should also contribute to our success as we move forward through the clinical and regulatory process for BICX102.”
 
Robert Giannini, chief science and technology officer, IRISYS,” said, “IRISYS is pleased to contribute its expertise to the development of BICX102, which promises to be a significant factor in addiction recovery and we believe it will aid in the effort to combat the national opioid crisis.”